Ganowa: inda aka yanke shawarar samarwa
Bayar da lasisi yana nuna gaskiyar matakin ganowa wanda ke raguwa lokacin da kwayar halitta ta kasance “dan takara kawai.” Analog na GLP-1 kamar bofanglutide shine jerin saura 30-da-rago tare da gyaran sarkar mai-acid-acid wanda ke ba da rabin rayuwar sati biyu.. Wannan gine-ginen yana daidai inda yanayin gazawar takamaiman peptide - haɗuwar hydrophobic yayin taro., yanke ko share jerin, ragowar abubuwan da aka lalata, Abubuwan da ke haifar da amsawar gefe daga matakin acylation - an ƙaddara tun kafin duk wani tsari na yin rajista.
Peptide Synthesis Ma'anar kasuwanci ita ce yarjejeniyar ba da lasisi tana canza tsarin ganowa yadda ya kamata zuwa shirin tare da haɓaka jama'a da ƙayyadaddun lokaci.. Da zarar mai lasisi ke da alhakin yin rajista, Dole ne a binciki jerin mafarin da hanyar gyara don kerawa, ba kawai aiki ba. peptide CRO wanda zai iya tantance jeri don yuwuwar roba, tuta ƙazanta kasada daga farko, da kuma kulle hanyoyin bincike na farko suna ba masu ƙirƙira hanya mafi sauƙi cikin wajibcin yarjejeniyar. Mahimmanci wannan kima yana faruwa ne yayin da ake ci gaba da inganta kwayoyin halitta, don haka sinadarai da aka ba da lasisi ga EU shine sinadarai da za a iya yin su a sikeli.
A aikace wannan yana nufin hanya da aikin yiwuwa na gefe-jeri, kimantar rashin tsarki-hadarin, da haɓaka hanyar farko don ainihi, tsarki, da abubuwa masu alaƙa. Idan dogon, hydrophobic, Multi-gyara jerin GLP-1 ba a taɓa tantance shi ba Peptides na roba kira, mai lasisi ya gano matsalar daga baya - a kwatankwacinsa, a cikin ci gaban tsari, ko mafi munin duka a cikin tambayar tsari. Samun wannan horo daidai yana ɗaya daga cikin mafi natsuwa amma mafi girman dalilai masu tasiri kamar wannan yarjejeniya.
Ci gaban tsari: hanyar ta zama kadara mai lasisi
Yarjejeniyar lasisi ta sanya tsarin masana'anta wani bangare na fakitin lasisi. Domin roba peptides, Hanyar ba ta dace da yarjejeniyar ba - babban kaso ne na abin da mai lasisi ke biya don haifuwa. Wannan shine inda zurfin tsari-ci gaba na peptide CRO ya zama mai yanke hukunci.
M-lokaci peptide kira (SPSS) Analog na GLP-1 ya dogara da sarkar ƙarami, yanke shawara tsakanin juna: ƙungiyar kariya da zaɓin guduro, hada biyu da deprotection kinetics, yanayi cleavage, dabarun tsarkakewa, da gishiri ko counter-ion form. Hanyar da ke aiki da kyau a ma'aunin milligram da wuya tana riƙe da aikin injiniya da sikelin kasuwanci. Masana'antar GLP-1 tana da ƙarfi-mai ƙarfi kuma sanannen kulawa ga ayyukan rukunin sa, wanda shine dalilin da ya sa Layer CDMO peptide - ɗimbin kayan aiki masu iya gina dogon lokaci, hadaddun peptides a sikelin kasuwanci - ya zama sanannen ƙulli ga ajin.
Don ba da lasisin mai ƙididdigewa zuwa Turai, Tambaya mai amfani ita ce ko kunshin tsari yana tafiya kamar yadda aka inganta, sunadarai masu kariya maimakon a matsayin girke-girke na dakin gwaje-gwaje. Anan ne aka ba da rahoton ci gaba, injiniyoyi da kuma batches masu girma dabam, kuma ingantattun sarrafawar nazari sun fara kama da ainihin abubuwan da ake iya bayarwa na ma'amala. Ƙarin sake fasalin tsari a sikelin, ƙarancin kasadar ƙasa akan kwatantawa daga baya. Kwararren bincike na peptide da abokin aikin masana'antu kamar Canje-canje na MOL, tare da tsantsar nazari don isarwa al'ada peptide kira a fadin ma'auni mai amfani, shine nau'in CRO wanda ke hana wannan hannun-kashe daga tsayawa - kuma wanda damarsa a ciki GLP-1 gyare-gyare da haɓaka ayyukan aiki nuna ko hanya zata iya tsira daga tafiya daga dakin gwaje-gwaje zuwa wani abu mai rijista.
Kwatanta: tabbatar da abin da aka canjawa wuri abu ɗaya ne
Da zarar tsari, site, albarkatun kasa, ko hanyoyin bincike sun canza yayin canja wuri, masu gudanarwa suna buƙatar mai lasisi don nuna cewa sabon abu ya yi daidai da na wanda ya samo asali. Don peptides na roba abu na miyagun ƙwayoyi ba shi da layin tantanin halitta don daidaita kwatancen; maimakon, ta Jagorar EMA akan haɓakawa da kera peptides na roba, Halaye tare da "aiki da gwajin nazari na al'ada" sun zama tushen nunin.
Wannan kwatancen yayi nisa da ƙarancin ƙarancin analog ɗin GLP-1 wanda halayen asibiti ya dogara da bayanin ƙazanta. Ko da a fili ƙananan canje-canje a cikin abubuwan SPPS ko a cikin jirgin tsarkakewa na iya canza tsarin da aka yanke., shafe peptides, isomers, oxidation ko hydrolysis kayayyakin, sauran reagents, matakan counter-ion, da sauran kaushi. Batch sãɓãwar launukansa yana da asali ga peptide kira, don haka motsa jiki kwatankwacin gaske tambayoyin gefe-da-gefe na bayanan ƙazanta da halayen sinadarai na physicochemical tsakanin kayan mai ƙirƙira da kayan da aka samar don kasuwa mai lasisi., goyan bayan bayanan kwanciyar hankali da, inda ya dace, daidaita aikin da ba na asibiti ba.
Don masu kirkiro peptide, Wannan matakin ya bayyana wane abokin tarayya na CRO zai iya gudanar da shirin kwatankwacin kwata-kwata. Yana buƙatar dakin gwaje-gwaje wanda ke sake haɓakawa ko gada hanyoyin nazarin tushen asali - HPLC da LC-MS ainihi da tsabta., peptide taswira, iyawa, ragowar mai narkewa da reagent cak, abun ciki na ruwa, counter-ion, endotoxin da bioburden - tare da sharuɗɗan karɓa na yau da kullun da gwajin daidaitattun ɗakunan gwaje-gwaje. A gwajin peptide iyawar da za ta iya haifar da karewa, ƙayyadaddun bayanan ƙididdiga na batch shine abin da ke juyar da da'awar kwatancen zuwa shaidar da ma'aikacin Turai zai karɓa maimakon tabbaci.. Samuwar Peptide
Canja wurin fasaha: sake gina shari'a, ba kwafi-paste ba
Masu gudanarwa da ƙwararrun CDMOs sun bayyana motsi tsarin magunguna tsakanin wurare azaman sake ginawa, ba hannun kashe takardu ba. Gidan yanar gizon ba zai iya aiwatar da bayanan mai tushe kawai ba; dole ne ya sake kafa tsarin a karkashin kayan aikinsa, guduro, tacewa, sauran ƙarfi handling, da jirgin tsarkakewa, kuma tabbatar da cewa yana samar da kayan daidai da ma'aunin GMP.
Canja wurin fasaha don irin wannan yarjejeniyar ba da lasisi ya haɗa ɗimbin sabis na buƙata: cikakken kunshin na batch records, master formula, tsarin sigogi, ƙayyadaddun kayan danye, m ingancin halaye, in-process controls, hanyoyin tsaftacewa, canja wurin hanyar nazari, da dabarun kwanciyar hankali - tare da horar da hannu-da-ido don ƙungiyar da ke karɓar damar sake fasalin tsarin a dogara. Kowane ɗayan waɗannan abubuwan shine wurin da shirin peptide zai iya raguwa cikin nutsuwa, rasa amfanin gona, tara kazanta, ko yawo cikin kwanciyar hankali ba tare da gazawa guda ɗaya ba.
Saƙon dabarun ga masu ƙirƙira shine cewa sharuɗɗan lasisi yakamata su bi diddigin zafin canja wuri. Abokin haɗin gwiwa wanda zai iya aiwatar da canjin shari'a tare da rubuce-rubucen haɓakawa da batches na haɓaka, kuma wanda tuni yana aiki ƙarƙashin sarrafawa, yanayin masana'anta bakararre, yana kawar da mafi yawan haɗarin cewa peptide mai lasisi ba zai gaza dasawa ba. Wannan kuma shine inda isarwa da haɗarin lokaci suka maida hankali - canja wuri galibi shine mafi tsayin sanda a cikin tantin lasisi, kuma ba za a iya rage shi ta hanyar ƙara kuɗi a ƙarshe ba.
Takamaiman takaddun ingancin yanki: EU da UK fayiloli ne daban daban
Babban sakamakon wannan yarjejeniya ta musamman shine yanki. Menarini 39 yankuna ba kasuwa ɗaya ba ne na ƙa'ida don sabon peptide roba: da EU/EEA da kuma Birtaniya kula da nasu izini da waƙoƙin dubawa. Hanyar EU tana gudana ta tsarin EMA (tsarin tsakiya ko na ƙasa) a kan jagorar roba-peptide na EMA da faɗuwar abubuwan sinadarai-na-ayyukan abubuwan tsammanin.. Birtaniya ta bi ta MHRA, wanda ke buƙatar izinin tallan kansa, GMP yarda, lasisin masana'anta ko mai shigo da kaya, da ƙwararrun mutum na saki.
A aikace, takardun lasisi sun rabu zuwa a duniya/master CMC kunshin kuma ƙayyadaddun shaida na tsari na yanki. Abubuwan da aka raba - Module na CTD 3 lissafin abubuwan da ke tattare da magunguna, halayyar, ƙayyadaddun bayanai, hanyoyin nazari, nazarin tsari, kazanta, da kwanciyar hankali - za a iya sake amfani da su a cikin yankuna. Amma kowane yanki sai ya zama a kan nasa appendices: Takaddun shaida na GMP da tarihin dubawa ga kowane masana'anta da rukunin gwaji da ke cikin waccan kasuwa, ingantattun yarjejeniyoyin da ke bayyana alhakin kera, saki, sabawa, canza iko, da korafi, da Takaddun Sakin QP/Batch-Resease na Burtaniya. Tabbatarwa guda ɗaya ko ingantaccen rikodin tsari na iya buƙatar yin magana da hukumomi daban-daban guda biyu waɗanda za su bincika sakin layi ɗaya don fa'idodi daban-daban..
Don mai kirkiro peptide, wannan yana nufin abokin tarayya na CRO dole ne ya kasance da ƙwarewa wajen samar da ingantattun takaddun shaida waɗanda ke tafiya cikin tsafta zuwa ƙaddamar da EU CTD da kuma daidaitaccen fayil ɗin UK - ba guda ɗaya na "Turai" ba.. Ikon ƙayyadaddun ƙayyadaddun ƙayyadaddun bayanai, ainihin tsari bincike, da tsarin ingantattun ladabtarwa a matakin sinadarai na miyagun ƙwayoyi sune tushen da ke sa fayilolin biyu su tabbata. Lokacin a inganci An gina shirin a kusa da bayanan nazari na gaske maimakon takaddun da aka haɗa don kasuwa ɗaya, shaida iri ɗaya na iya yiwa masu bitar EMA da MHRA hidima ba tare da an sake rubuta su ba ko, mafi muni, saba.
Abin da wannan yarjejeniya ke nunawa don shirin ku
Karanta bayan EUR 726 miliyan kuma ƙarshe ɗaya ya fito waje: lasisi shine inda kwayoyin peptide ya daina zama sha'awar kimiyya kuma ya zama wajibi na masana'antu da ka'idoji tare da kwanaki masu wahala.. Mai ƙirƙira wanda ke kula da matakai biyar na sama a matsayin wani ɓangare na aikin injiniya na yarjejeniyar, maimakon kamar yadda bayan tunani za a warware ta kowane mai siyarwa ne mafi arha, shi ne wanda ke kiyaye tsarin lokacinsa da sinadarai ta hanyar tsallake-tsallake hannu.
Ƙarfin da ke tattare da tari a kusa da jigogi iri ɗaya yakamata mai haɓakawa ya kamata ya kula da su: goyon bayan gano masana'anta-sane, haɓaka tsarin haɓakawa da haɓakawa don dogon gyare-gyaren peptides, kwatankwacin karewa da canja wurin nazari, canja wurin fasaha mai horo a ƙarƙashin yanayin sarrafawa, da takaddun da ke gamsar da masu tantance EU da Burtaniya a lokaci guda.
Idan kuna shirya GLP-1 ko hadadden peptide da aka gyara don hanyar ba da lasisi - ko cancantar abokin tarayya don ɗaukar ɗaya - mataki na farko mai aiki shine nazarin yuwuwar fasaha na jerinku da tsarin yanzu akan waɗannan buƙatun canja wuri.. Ci gaban yarjejeniya kamar Menarini da Gan & Lee ba'a iyakance ga kamfanoni biyu ba; yana daidaita ma'auni na yadda masu ƙirƙira peptide a ko'ina yakamata suyi tsammanin kashe hannun lasisin suyi aiki..
